A research and development medical cannabis company is as new now as web-based businesses were in the early ‘90s. So, what is it like to be running a company in this very early stage of a brand new industry?
I asked Raymond C. Dabney, President & CEO of Cannabis Science exactly that and here is what he had to say about being part of a historic time in this incredibly exciting industry.
What is Cannabis Science?
Cannabis Science is a forward thinking company specializing in cannabis formulation-based drug development and related consulting. We are working diligently to bring cannabinoid-based medicines to the forefront of the medical community’s attention by developing unique cannabis based approaches to treat the world’s most deadly illnesses.
Through drug development, medicinal characterization, and clinical research, our goal is to develop, produce, and commercialize innovative therapeutic approaches for treatment of illnesses caused by infections and age-related illness. Our initial focus is on skin cancers and neurological conditions with future endeavors to include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder, and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.
How many states allow legal medicinal cannabis?
Right now, 23 states permit medical cannabis to be used. What we are doing at Cannabis Science is creating a product line for physicians to prescribe to their patients with confidence. We are very proud of our efforts and our patient-portal of success stories continues to grow with more patients sharing their experiences using cannabis as an alternative medicinal method for short-term and chronic effective pain relief. It’s a very exciting time.
What are the most common health issues in which Cannabis can provide relief?
Cannabinoid-based medicines have been helpful in easing the symptoms of numerous conditions including Cancer, HIV-AIDS, Asthma, Tourettes and Glaucoma. Additionally, scientists recently found that topical cannabinoid-based preparations can be effective against MRSI, the deadly antibiotic-resistant flesh-eating disease. Other topical applications, which are largely non-psychoactive, would target localized pain, such as arthritis and burns, as well as neuropathic pain, for which there are few effective treatments.
When you share your title and company name with strangers — what reaction do you typically get?
Surprise and curiosity very quickly turns to keen interest. Everyone understands the crisis of pain and the traditional “go-to” solution of pills, which has the potential of leading to addiction. People want to know how Cannabinoid-based medicines can be applied, in controlled doses, through approved pharmaceutical manufacturing to help them and their loved ones. Finding new ways to deal with health issues is something everyone wants to know more about and supports.
How were you able to attract such formidable experts to your Board?
Medical professionals love being part of the unknown because they get to discover more answers and Cannabis Science provides the perfect platform. We are proud to have experts and visionaries helping us on our Scientific Advisory Board including former Assistant Surgeon General, Dr. Roscoe Moore, Jr. who served under three Presidents.
You were just appointed to the CFA Africa Healthcare Infrastructure Committee. Tell us about that.
I am honored to have been named as Vice Chair of this tremendously important committee. My company and foundation are committed to responding with urgency and seriousness of purpose to support long-term efforts to rebuild Africa’s healthcare infrastructure along the priorities established by the Africa Healthcare Infrastructure Committee. This work will include education and training to replace workers lost in epidemics such as the HIV/AIDS and the Ebola epidemics, revitalization of agriculture, and leadership training. A healthy and vibrant Africa is good for everybody. Imagine the potential of untapped resources of Africa making their fair share contribution to the global economy, including in agricultural production, drug manufacturing and distribution. As CEO of Cannabis Science, we are seeking new regions to develop business for low-cost cannabis-based therapeutics, which could also meet the acute shortage of pain medications along with many other critical ailment treatments in Africa.
For more info, visit: Cannabis Science.